> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Regulatory Review Period Determined for Xuriden
- URL: https://www.fdaweb.com/regulatory-review-period-determined-for-xuriden/
- Published: 2017-11-29T12:00:00.000Z
- Updated: 2026-09-14T23:04:03.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5140222

*Federal Register* notice: FDA has determined that the regulatory review period for patent extension purposes for Wellstat Therapeutics’ Xuriden (uridine triacetate), indicated for treating hereditary orotic aciduria, is 8,494 days. Of this, 8,254 days occurred during the testing phase and 240 days occurred during the approval phase. To view the notice, click [here](https://www.gpo.gov/fdsys/pkg/FR-2017-11-29/pdf/2017-25770.pdf?ref=fdaweb.com).